Advanz Pharma (OTCMKTS:CXRXF) Lowered to Sell at Zacks Investment Research
According to Zacks, “Advanz Pharma Corp. is a specialty pharmaceutical company. It operates primarily in Bridgetown, Barbados; London, England and Mumbai, through its subsidiaries. Advanz Pharma Corp., formerly known as Concordia International Corp., is based in LONDON, UNITED KINGDOM. “
Separately, ValuEngine upgraded shares of Advanz Pharma from a buy rating to a strong-buy rating in a research report on Wednesday, September 4th.
Advanz Pharma (OTCMKTS:CXRXF) last released its earnings results on Wednesday, August 7th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.03. Advanz Pharma had a net margin of 322.43% and a negative return on equity of 60.90%. The company had revenue of $131.08 million for the quarter, compared to the consensus estimate of $127.00 million. Research analysts forecast that Advanz Pharma will post -2.09 EPS for the current year.
About Advanz Pharma
ADVANZ PHARMA Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company operates through two segments, Concordia International and Concordia North America. The Concordia International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies.
Read More: How to calculate compound interest
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Advanz Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advanz Pharma and related companies with MarketBeat.com's FREE daily email newsletter.